Replies to post #340255 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Doc328: Do you believe that the following is in general true or false???

Alzheimer's disease is easier to treat at the earliest stage possible. See the image below to understand why this is true.

The above is especially true if you are targeting upstream MOA with precision medicine.



The Anavex Blarcamesine Phase 2b/3 trial is for early stage Alzheimer's disease with baseline MMSE scores of 20 to 28 inclusive

Prevention of Alzheimer's disease via Blarcamesine or Anavex 3-71 would be the earliest stage possible.

Good luck and GOD bless

[Jonjones325]

Thanks Doc. Even though the data remains blind up to the point you mentioned, I would imagine the company has a fairly good to great idea about the results.

Wouldn’t the baseline measurements taken at the beginning of the OLE give away the results since it can be compared to the original baseline before the trial started?

TIA